Welcome to Francis Academic Press

Frontiers in Medical Science Research, 2022, 4(12); doi: 10.25236/FMSR.2022.041206.

Development of COVID-19 Recombinant Subunit Vaccine and Adjuvant


Xin Zhao1, Lianyan Wang2, Yanhua Zhu1

Corresponding Author:
Yanhua Zhu

1Heilongjiang University of Chinese Medicine, Harbin, 150000, Heilongjiang, China

2Institute of Process Engineering, Chinese Academy of Sciences, Beijing, China


At present, vaccination is the only effective and low-cost way to prevent and treat COVID-19. At present, the vaccines vaccinated on a large scale are inactivated COVID-19 vaccines, which have the risk of insufficient immunogenicity, low neutralizing antibody production level and short maintenance time, and incomplete pathogen inactivation leading to adverse reactions. The recombinant subunit vaccine can effectively overcome the problem of poor safety of inactivated virus vaccines by using immune epitope proteins or peptides as recognition epitopes, and with the assistance of appropriate adjuvants, it can produce high levels of neutralizing antibodies and maintain good immune memory. This paper will review the application of recombinant protein antigen of COVID-19 virus and various adjuvants, and prospect the future application of recombinant protein vaccine.


COVID-19, Subunit vaccine, Adjuvant

Cite This Paper

Xin Zhao, Lianyan Wang, Yanhua Zhu. Development of COVID-19 Recombinant Subunit Vaccine and Adjuvant. Frontiers in Medical Science Research (2022) Vol. 4, Issue 12: 35-40. https://doi.org/10.25236/FMSR.2022.041206.


[1] Walls A C, Park Y J, Tortorici M A, et al. Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein [J]. Cell, 2020, 181(2): 281-292.e286.

[2] Wrapp D, Wang N, Corbett K S, et al. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation [J]. Science, 2020, 367(6483): 1260-1263.

[3] Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor [J]. Cell, 2020, 181(2): 271-280.e278.

[4] Ruan Y J, Wei C L, Ee A L, et al. Comparative full-length genome sequence analysis of 14 SARS coronavirus isolates and common mutations associated with putative origins of infection [J]. Lancet, 2003, 361(9371): 1779-1785.

[5] Yang Y, Zang J, Xu S, et al. Elicitation of Broadly Neutralizing Antibodies against B.1.1.7, B.1.351, and B.1.617.1 SARS-CoV-2 Variants by Three Prototype Strain-Derived Recombinant Protein Vaccines [J]. Viruses, 2021, 13(8): 

[6] Haun B K, Lai C Y, Williams C A, et al. CoVaccine HT™ adjuvant potentiates robust immune responses to recombinant SARS-CoV-2 Spike S1 immunisation [J]. bioRxiv, 2020, 

[7] Wørzner K, Sheward D J, Schmidt S T, et al. Adjuvanted SARS-CoV-2 spike protein elicits neutralizing antibodies and CD4 T cell responses after a single immunization in mice [J]. EBioMedicine, 2021, 63(103197.

[8] Nanishi E, Borriello F, O'meara T R, et al. Alum:CpG adjuvant enables SARS-CoV-2 RBD-induced protection in aged mice and synergistic activation of human elder type 1 immunity [J]. bioRxiv, 2021, 

[9] Lal H, Cunningham A L, Godeaux O, et al. Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults [J]. N Engl J Med, 2015, 372(22): 2087-2096.

[10] Van Hoeven N, Fox C B, Granger B, et al. A Formulated TLR7/8 Agonist is a Flexible, Highly Potent and Effective Adjuvant for Pandemic Influenza Vaccines [J]. Sci Rep, 2017, 7(46426.

[11] Pino M, Abid T, Pereira Ribeiro S, et al. A yeast expressed RBD-based SARS-CoV-2 vaccine formulated with 3M-052-alum adjuvant promotes protective efficacy in non-human primates [J]. Sci Immunol, 2021, 6(61): 

[12] Routhu N K, Cheedarla N, Bollimpelli V S, et al. SARS-CoV-2 RBD trimer protein adjuvanted with Alum-3M-052 protects from SARS-CoV-2 infection and immune pathology in the lung [J]. Nat Commun, 2021, 12(1): 3587.

[13] Kelly H G, Kent S J, Wheatley A K. Immunological basis for enhanced immunity of nanoparticle vaccines [J]. Expert Rev Vaccines, 2019, 18(3): 269-280.

[14] Walls A C, Fiala B, Schäfer A, et al. Elicitation of Potent Neutralizing Antibody Responses by Designed Protein Nanoparticle Vaccines for SARS-CoV-2 [J]. Cell, 2020, 183(5): 1367-1382.e1317.